 Home > Active Ingredient News > Blood System > JCO: Phase 3 TOURMALINE-MM1 trial of patients with relapsed/refractory MM who were treated with ixazomib-lenalidomide-dexamethasone in the final analysis of overall survival

JCO: Phase 3 TOURMALINE-MM1 trial of patients with relapsed/refractory MM who were treated with ixazomib-lenalidomide-dexamethasone in the final analysis of overall survival

 Last Update: 2021-06-21
 Source: Internet
 Author: User

Tags

single cell analysis

3 en 1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The double-blind, placebo-controlled Phase 3 TOURMALINE-MM1 study showed that ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) regimen can significantly improve relapse/refractory multiples compared with placebo-Rd Progression-free survival of patients with myeloma

In this trial, patients were randomly assigned to ixazomib-Rd group (360 people) or placebo-Rd group (362 people), and based on the number of previous treatments (1 vs 2/3), proteasome inhibitor (PI ) Stratification of exposure history (yes vs.

Overall survival of the intention-to-treat population and different subgroups

After a median follow-up of 85 months, the median OS of the ixazomib-Rd group and the placebo-Rd group were 53.

A lower hazard ratio was observed in a predetermined subgroup, suggesting that the ixazomib-Rd regimen has a greater OS benefit compared with placebo-Rd.

Overall survival of patients with various high-risk cytogenetic characteristics

After the study treatment, 71.

The new incidence of primary malignant tumors was similar in the two groups: ixazomib-Rd group (10.

In summary, in this analysis, the progression-free survival benefit of ixazomib-Rd and placebo-Rd did not translate into a statistically significant OS benefit

Subgroup of patients with poor prognostic factors can get greater OS benefit from ixazomib-Rd treatment Subgroup of patients with poor prognostic factors can get greater OS benefit from ixazomib-Rd treatment

Original source:

Paul G.

Final Overall Survival Analysis of the TOURMALINE- MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

GUANFACINE HCL Factory Price Pharmaceutical Chemical Purity Degree 99%

CAS No.: 29110-48-3

Pharmacy Grade

$10-13/G FOB

Ticlopidine

CAS No.: 55142-85-3

$1/KG EXW

4-(Aminomethyl)benzoic acid

CAS No.: 56-91-7

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.